ARIPIPRAZOLE SANDOZ 20 Israel - English - Ministry of Health

aripiprazole sandoz 20

novartis israel ltd - aripiprazole - tablets - aripiprazole 20 mg - aripiprazole - aripiprazole sandoz is indicated for the treatment of schizophrenia, for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in patient who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.aripiprazole sandoz is indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (mdd). efficacy was established in two 6-week trials in adults with mdd who had an inadequate response to antidepressant therapy during the current episode.aripiprazole sandoz is indicated for the treatment of irritability associated with autistic disorder. efficacy was established in two 8-week trials in pediatric patients (aged 6 to 17 years) with irritability associated with autistic disorder (including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods).

APO-ARIPIPRAZOLE 20 mg aripiprazole tablets bottle Australia - English - Department of Health (Therapeutic Goods Administration)

apo-aripiprazole 20 mg aripiprazole tablets bottle

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 20 mg - tablet, uncoated - excipient ingredients: tartaric acid; croscarmellose sodium; microcrystalline cellulose; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

APO-ARIPIPRAZOLE 30 mg aripiprazole tablets bottle Australia - English - Department of Health (Therapeutic Goods Administration)

apo-aripiprazole 30 mg aripiprazole tablets bottle

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 30 mg - tablet, uncoated - excipient ingredients: iron oxide red; tartaric acid; croscarmellose sodium; microcrystalline cellulose; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

APO-ARIPIPRAZOLE 10 mg aripiprazole tablets bottle Australia - English - Department of Health (Therapeutic Goods Administration)

apo-aripiprazole 10 mg aripiprazole tablets bottle

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 10 mg - tablet, uncoated - excipient ingredients: iron oxide red; tartaric acid; microcrystalline cellulose; croscarmellose sodium; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

APO-ARIPIPRAZOLE 2 mg aripiprazole tablets bottle Australia - English - Department of Health (Therapeutic Goods Administration)

apo-aripiprazole 2 mg aripiprazole tablets bottle

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 2 mg - tablet, uncoated - excipient ingredients: tartaric acid; microcrystalline cellulose; croscarmellose sodium; indigo carmine aluminium lake; iron oxide yellow; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

APO-ARIPIPRAZOLE 5 mg aripiprazole tablets bottle Australia - English - Department of Health (Therapeutic Goods Administration)

apo-aripiprazole 5 mg aripiprazole tablets bottle

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; indigo carmine aluminium lake; croscarmellose sodium; tartaric acid; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

APO-ARIPIPRAZOLE 2 mg aripiprazole tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-aripiprazole 2 mg aripiprazole tablets blister pack

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 2 mg - tablet, uncoated - excipient ingredients: indigo carmine aluminium lake; tartaric acid; iron oxide yellow; croscarmellose sodium; microcrystalline cellulose; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

APO-ARIPIPRAZOLE 15 mg aripiprazole tablets bottle Australia - English - Department of Health (Therapeutic Goods Administration)

apo-aripiprazole 15 mg aripiprazole tablets bottle

arrotex pharmaceuticals pty ltd - aripiprazole, quantity: 15 mg - tablet, uncoated - excipient ingredients: iron oxide yellow; microcrystalline cellulose; croscarmellose sodium; tartaric acid; magnesium stearate - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,acute treatment of manic or mixed episodes associated with bipolar i disorder in adults as monotherapy and in combination with lithium or valproate;,maintenance treatment of manic or mixed episodes in bipolar i disorder in adults as monotherapy.

Aripiprazole Uriach 5mg tablets Malta - English - Medicines Authority

aripiprazole uriach 5mg tablets

j. uriach y compania, s.a. av. cami reial, 51-57 08184 - palau-solita i plegamans, barcelona, spain - aripiprazole - tablet - aripiprazole 5 mg - psycholeptics

Aripiprazole Uriach 10mg tablets Malta - English - Medicines Authority

aripiprazole uriach 10mg tablets

j. uriach y compania, s.a. av. cami reial, 51-57 08184 - palau-solita i plegamans, barcelona, spain - aripiprazole - tablet - aripiprazole 10 mg - psycholeptics